Advertisement

Clinical efficacy and safety analysis of CT-guided 125I implantation in the treatment of recurrent or metastatic pelvic malignant tumor

  • Author Footnotes
    # Co first authors are Shenghe Zhang and Songbai Chen. Both of them have equally important contributions to this article.
    Shenghe Zhang
    Footnotes
    # Co first authors are Shenghe Zhang and Songbai Chen. Both of them have equally important contributions to this article.
    Affiliations
    Department of Intervention, Affiliated Zhongshan Hospital of Dalian University, Dalian, China
    Search for articles by this author
  • Author Footnotes
    # Co first authors are Shenghe Zhang and Songbai Chen. Both of them have equally important contributions to this article.
    Songbai Chen
    Footnotes
    # Co first authors are Shenghe Zhang and Songbai Chen. Both of them have equally important contributions to this article.
    Affiliations
    Department of Intervention, Affiliated Zhongshan Hospital of Dalian University, Dalian, China
    Search for articles by this author
  • Ruoyu Wang
    Correspondence
    Corresponding authors at: Department of Intervention, Affiliated Zhongshan Hospital of Dalian University, Dalian 116001, China (C. Li); Department of Medical Oncology, Affiliated Zhongshan Hospital of Dalian University, Dalian, China (R. Wang).
    Affiliations
    Department of Medical Oncology, Affiliated Zhongshan Hospital of Dalian University, Dalian, China
    Search for articles by this author
  • Zhe Wang
    Affiliations
    Department of Medical Oncology, Affiliated Zhongshan Hospital of Dalian University, Dalian, China
    Search for articles by this author
  • Jun Zhou
    Affiliations
    Department of Intervention, Affiliated Zhongshan Hospital of Dalian University, Dalian, China
    Search for articles by this author
  • Chuang Li
    Correspondence
    Corresponding authors at: Department of Intervention, Affiliated Zhongshan Hospital of Dalian University, Dalian 116001, China (C. Li); Department of Medical Oncology, Affiliated Zhongshan Hospital of Dalian University, Dalian, China (R. Wang).
    Affiliations
    Department of Intervention, Affiliated Zhongshan Hospital of Dalian University, Dalian, China
    Search for articles by this author
  • Author Footnotes
    # Co first authors are Shenghe Zhang and Songbai Chen. Both of them have equally important contributions to this article.
Published:December 29, 2022DOI:https://doi.org/10.1016/j.brachy.2022.10.007

      Abstract

      PURPOSE

      This study was conducted to evaluate the clinical efficacy and safety of computed tomography (CT)-guided 125I implantation in the treatment of recurrent or metastatic pelvic malignant tumor.

      METHODS AND MATERIALS

      This retrospective study analyzed the data of 30 patients with recurrent and metastatic pelvic malignant tumor who were treated with CT-guided 125I implantation between January 2016 and December 2020. Disease control rate, objective remission rate, overall survival (OS), pain relief rate, quality of life score, and complications were evaluated after the followup.

      RESULTS

      Median followup was 20.1 (7–30) months. Disease control rate was 86.67% at 6 months. Objective response rates at 1, 3, and 6 months were 36.67%, 60%, and 56.67%, respectively. OS rates at 12 and 24 months were 76.67% (23/30) and 33.33% (10/30), respectively. Progression-free survival rates at 12 and 24 months were 63.33% (19/30) and 33.33% (10/30), respectively. Postoperative pain relief rate was 86.67% (26/30). There were no major bleeding, pelvic abscess, intestinal fistula, intestinal perforation, and other serious complications.

      CONCLUSIONS

      CT-guided 125I seed implantation in the treatment of patients with pelvic malignant tumor is a simple operation and less traumatic and can improve patients’ quality of life and reduce tumor load.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Brachytherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Cohen AC
        • Roane BM
        • Leath 3rd, CA
        Novel therapeutics for recurrent cervical cancer: moving towards personalized therapy.
        Drugs. 2020; 80: 217-227
        • Gadducci A
        • Cosio S.
        Pharmacological treatment of patients with metastatic, recurrent or persistent cervical cancer not amenable by surgery or radiotherapy: state of art and perspectives of clinical research.
        Cancers. 2020; 12: 2678
        • Rombouts AJM
        • Hugen N
        • van Beek JJP
        • et al.
        Does pelvic radiation increase rectal cancer incidence? - A systematic review and meta-analysis.
        Cancer Treatment Rev. 2018; 68: 136-144
        • Wang H
        • Wang L
        • Jiang Y
        • et al.
        Long-term outcomes and prognostic analysis of computed tomography-guided radioactive (125)I seed implantation for locally recurrent rectal cancer after external beam radiotherapy or surgery.
        Front Oncol. 2020; 10540096
        • Yanhao L.
        • Junjie W.
        Advances in brachytherapy for recurrent cervical cancer.
        Chin. J. Radiat. Oncol. 2021; 30: 297-300
        • Wang J
        • Zhang F
        • Guo J
        • et al.
        Expert consensus workshop report: guideline for three-dimensional printing template-assisted computed tomography-guided (125)I seeds interstitial implantation brachytherapy.
        J Cancer Res Ther. 2017; 13: 607-612
        • Eisenhauer EA
        • Therasse P
        • Bogaerts J
        • et al.
        New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
        Eur J Cancer (Oxford, England: 1990). 2009; 45: 228-247
        • Cox JD
        • Stetz J
        • Pajak TF.
        Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC).
        Int J Radiat Oncol Biol Phys. 1995; 31: 1341-1346
        • Karcioglu O
        • Topacoglu H
        • Dikme O
        • et al.
        A systematic review of the pain scales in adults: which to use?.
        Am J Emerg Med. 2018; 36: 707-714
        • Chao X
        • Fan J
        • Song X
        • et al.
        Diagnostic strategies for recurrent cervical cancer: a cohort study.
        Front Oncol. 2020; 10591253
        • Benson AB
        • Venook AP
        • Al-Hawary MM
        • et al.
        NCCN guidelines insights: rectal cancer, Version 6.2020.
        J Natl Comprehens Cancer Netw: JNCCN. 2020; 18: 806-815
        • Benson AB
        • Venook AP
        • Al-Hawary MM
        • et al.
        Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology.
        J Natl Comprehens Cancer Netw: JNCCN. 2021; 19: 329-359
        • Peacock O
        • Waters PS
        • Kong JC
        • et al.
        Complications and 5-year survival after radical resections which include urological organs for locally advanced and recurrent pelvic malignancies: analysis of 646 consecutive cases.
        Tech Coloproctol. 2020; 24: 181-190
        • Voss RK
        • Lin JC
        • Roper MT
        • et al.
        Adjuvant chemotherapy does not improve recurrence-free survival in patients with stage 2 or stage 3 rectal cancer after neoadjuvant chemoradiotherapy and total mesorectal excision.
        Dis Colon Rectum. 2020; 63: 427-440
        • Thamronganantasakul K
        • Supakalin N
        • Kietpeerakool C
        • et al.
        Extended-field radiotherapy for locally advanced cervical cancer.
        Cochrane Database Syst Rev. 2018; 10CD012301
        • Wang J
        • Chai S
        • Zheng G
        • et al.
        Expert consensus statement on computed tomography-guided (125)I radioactive seeds permanent interstitial brachytherapy.
        J Cancer Res Ther. 2018; 14: 12-17
        • Chen Y
        • Jiang Y
        • Ji Z
        • et al.
        Efficacy and safety of CT-guided (125)I seed implantation as a salvage treatment for locally recurrent head and neck soft tissue sarcoma after surgery and external beam radiotherapy: a 12-year study at a single institution.
        Brachytherapy. 2020; 19: 81-89
        • Li CG
        • Zhou ZP
        • Jia YZ
        • et al.
        Radioactive (125)I seed implantation for locally advanced pancreatic cancer: a retrospective analysis of 50 cases.
        World J Clin Cases. 2020; 8: 3743-3750
        • Wang H.
        • Lu J.
        • Zheng X.
        • et al.
        Oligorecurrence non-small cell lung cancer after failure of first-line chemotherapy: computed tomography-guided I seed implantation vs. Second-Line Chemotherapy.
        Front. Oncol. 2020; 10: 470
        • Wang R.
        • Zhu J.
        • Yang S.
        • et al.
        Therapeutic effects and prognostic factors of I brachytherapy for pelvic recurrence after early cervical cancer surgery.
        Sci. Rep. 2021; 11: 11356
        • Qu A
        • Jiang P
        • Sun H
        • et al.
        Efficacy and dosimetry analysis of image-guided radioactive 125I seed implantation as salvage treatment for pelvic recurrent cervical cancer after external beam radiotherapy.
        J Gynecol Oncol. 2019; 30: e9
        • Chuang L
        • Ruoyu W
        • Zhe W
        • et al.
        (125)I implantation under computed tomography guidance to treat patients with recurrent pelvic tumors: retrospective analysis of clinical results.
        J Cancer Res Ther. 2019; 15: 1496-1500